How to Get Lantus (Insulin Glargine) in Colorado

What Exactly Is Lantus and Why Is It Prescribed?

Lantus is a once-daily, long-acting basal insulin used to control fasting blood glucose in adults and children aged 6 and older with type 1 or type 2 diabetes. Its active ingredient, insulin glargine, is a recombinant human insulin analogue with a prolonged, peakless action profile lasting approximately 24 hours. Sanofi received original FDA approval for Lantus in April 2000, and the current prescribing information is maintained on the FDA accessdata portal 1.

The ORIGIN trial (N=12,537) published in the New England Journal of Medicine in 2012 randomized participants with dysglycemia to insulin glargine or standard care and found that glargine reduced HbA1c by a mean of 0.67 percentage points more than standard care at six years, with a median fasting glucose of 5.3 mmol/L in the glargine group 2. ORIGIN also demonstrated cardiovascular neutrality: the hazard ratio for the primary composite cardiovascular outcome was 1.02 (95% CI 0.94 to 1.11, P<0.001 for noninferiority) 2. That trial enrolled patients across 40 countries over a median 6.2 years, making it the largest long-term safety study of basal insulin to date.

Clinically, basal insulin is the backbone of glycemic management for type 1 diabetes and an established second-line or third-line agent for type 2 diabetes when oral agents or GLP-1 receptor agonists fail to reach targets. The American Diabetes Association's 2024 Standards of Care in Diabetes (section 9) state: "Insulin therapy is required for all people with type 1 diabetes and for many with type 2 diabetes" 3.

Dosing is individualized. A common starting point for type 2 diabetes is 10 units subcutaneously at bedtime, titrated by 2 units every 3 days until fasting glucose reaches target (typically 80 to 130 mg/dL per ADA 2024 targets) 3. Type 1 patients typically receive 40 to 50 percent of their total daily insulin requirement as basal glargine.

Who Can Prescribe Lantus in Colorado?

Any fully licensed Colorado prescriber with authority to write Schedule V or non-scheduled prescription drugs may prescribe Lantus. That group includes MDs, DOs, nurse practitioners (NPs) with full practice authority, physician assistants (PAs) operating under a collaboration agreement, and certified nurse midwives (CNMs) within their scope. Colorado granted NPs full independent practice authority in 2010, removing the requirement for a supervising physician signature on most prescriptions, including insulin 4.

Telehealth prescribers must hold a valid Colorado medical or advanced-practice license. The Colorado Department of Regulatory Agencies (DORA) does not require an initial in-person visit before a telehealth provider prescribes a non-controlled medication such as insulin. A synchronous video or telephone visit satisfies the Colorado standard for establishing a valid patient-provider relationship under Colorado Revised Statutes 12-240-107 5.

Endocrinologists are the most common specialists managing insulin-dependent diabetes, but primary care physicians initiate the majority of basal insulin prescriptions in practice. A 2021 JAMA Internal Medicine analysis found that 73 percent of basal insulin starts in the United States are written by primary care clinicians rather than endocrinologists 6.

How to Get a Lantus Prescription in Colorado: Step by Step

Getting Lantus in Colorado follows a predictable path. The steps below apply whether you see a provider in person or via telehealth.

Step 1. Schedule a visit. Book an appointment with a Colorado-licensed prescriber. Telehealth platforms serving Colorado can often schedule same-day or next-day consultations for established diabetes patients.

Step 2. Gather your records. Bring or upload recent lab work (HbA1c within 90 days, fasting glucose, a basic metabolic panel), your current medication list, and any prior diabetes diagnoses or specialist notes. Providers assess renal function before prescribing because severe renal impairment alters insulin clearance 7.

Step 3. Complete the clinical visit. The provider reviews your history, confirms or establishes a diabetes diagnosis, and selects an appropriate insulin regimen. Expect a discussion of injection technique, glucose monitoring frequency, and hypoglycemia recognition. The ADA 2024 Standards recommend self-monitoring of blood glucose at least four times daily for patients on basal-bolus regimens 3.

Step 4. Receive the prescription. The provider sends an electronic prescription (e-Rx) directly to your chosen Colorado pharmacy. Under Colorado law, insulin prescriptions may be written for up to a 90-day supply.

Step 5. Pick up or receive delivery. Retail pharmacies typically dispense Lantus same-day if stock is available. Mail-order pharmacies (CVS Caremark, Express Scripts, Amazon Pharmacy) deliver within 5 to 10 business days in Colorado.

Labs Required Before Starting Lantus in Colorado

Labs are not a legal prerequisite to receiving a Lantus prescription, but every responsible prescriber orders baseline labs before initiating insulin. The standard panel includes HbA1c, fasting plasma glucose, comprehensive metabolic panel (CMP) for kidney and liver function, a complete blood count, and a lipid panel.

Renal function deserves specific attention. Insulin is partially cleared by the kidneys; patients with an eGFR <30 mL/min/1.73 m2 may require dose reductions and more frequent monitoring 7. The FDA prescribing label for Lantus includes a precaution for renal impairment 1.

Hepatic impairment similarly affects glucose counterregulation. Patients with cirrhosis or ALT greater than three times the upper limit of normal warrant closer titration and monitoring 8.

Thyroid function (TSH) is often ordered in newly diagnosed type 1 patients given the co-occurrence of autoimmune thyroid disease, with a prevalence of approximately 17 to 30 percent in type 1 diabetes 9.

A urinalysis with microalbumin-to-creatinine ratio identifies early diabetic nephropathy, which changes the urgency of glycemic targets. The ADA 2024 Standards recommend annual urine albumin assessment in all patients with type 1 diabetes of more than five years' duration and in all patients with type 2 diabetes at diagnosis 3.

Telehealth Options for Lantus in Colorado

Colorado is one of the more telehealth-friendly states in the country. The state joined the Interstate Medical Licensure Compact, allowing out-of-state physicians to obtain a Colorado license more quickly 5. Colorado also expanded telehealth coverage parity during the COVID-19 public health emergency and made many of those expansions permanent through House Bill 22-1302.

A 2022 analysis in the Annals of Internal Medicine found that telehealth diabetes visits achieved equivalent HbA1c reductions compared to in-person visits (mean difference: 0.04 percentage points, 95% CI -0.12 to 0.20) over six months in a cohort of 14,306 patients 10. For basal insulin management specifically, telehealth platforms can handle dose titration, prescription renewals, and lab review with the same clinical rigor as an office setting.

When choosing a telehealth provider for Lantus in Colorado, confirm that the platform employs or partners with Colorado-licensed prescribers (not just licensed in a different state), sends prescriptions electronically to Colorado pharmacies, and offers asynchronous messaging between visits for titration questions. Platforms that integrate continuous glucose monitor (CGM) data into their portal give prescribers cleaner titration data between scheduled visits.

Most telehealth visits for insulin management cost between $50 and $150 out of pocket if not covered by insurance. Colorado commercial insurers are required to reimburse telehealth visits at parity with in-person visits under state law 5.

Colorado Insurance Coverage and Prior Authorization for Lantus

Coverage for Lantus varies significantly by payer. The sections below break down the main payer types in Colorado.

Commercial insurance. Most commercial plans in Colorado cover Lantus on Tier 2 or Tier 3 of their formulary. Many have shifted preferred formulary status to biosimilar insulin glargine products (Basaglar, Semglee, Rezvoglar) to control costs. If your plan lists Lantus on a non-preferred tier, your prescriber can submit a prior authorization (PA) requesting brand Lantus on clinical grounds, such as documented adverse response to biosimilars or patient stability on brand Lantus.

Prior authorization documentation. Standard PA packets for Lantus in Colorado typically require: current HbA1c, fasting glucose logs or CGM download from the past 30 days, documentation of the diabetes type and duration, a list of other diabetes medications tried, and a clinical narrative explaining why biosimilar switching is not appropriate. Per the Colorado Division of Insurance, commercial insurers must respond to PA requests within 72 hours for urgent cases and 15 calendar days for standard requests 11.

Health First Colorado (Medicaid). Colorado Medicaid covers insulin glargine for type 1 diabetes without prior authorization. For type 2 diabetes, Lantus requires a PA demonstrating failure of or contraindication to at least one oral agent (typically metformin) 12. Biosimilar insulin glargine (Semglee) holds preferred status on the Health First Colorado preferred drug list.

Medicare Part D. Most Part D plans cover some form of insulin glargine. The Inflation Reduction Act caps out-of-pocket insulin costs at $35 per month per insulin product for Medicare beneficiaries starting January 2023, which applies to Lantus and its biosimilars 13.

Uninsured or underinsured patients. Sanofi's Insulins Valyou Savings Program offers Lantus at $99 per month (up to 10 boxes of pens or 10 vials) for eligible cash-pay patients. The Sanofi Patient Assistance Program (PAP) provides free insulin to qualifying low-income patients. The Mark Cuban Cost Plus Drug Company does not currently carry brand Lantus, but carries insulin glargine biosimilars at substantially reduced prices.

Transferring a Lantus Prescription to Colorado

Moving to Colorado from another state does not void an existing Lantus prescription if the prescription was legally written in the originating state and has refills remaining. Colorado pharmacies may honor out-of-state prescriptions for non-controlled substances. The receiving Colorado pharmacist contacts the original pharmacy or prescriber to verify authenticity.

The most reliable path is to have your new Colorado provider issue a fresh prescription after a brief transfer-of-care visit, which also gives them the opportunity to review your current dose and make any needed adjustments. Telehealth platforms make this process fast: a 20-minute video visit is typically sufficient to review your diabetes history, confirm the Lantus dose, and issue a Colorado prescription.

Colorado law does not impose a quantity limit on insulin prescriptions shorter than a 90-day supply, and there is no state-mandated waiting period between fills for non-scheduled medications.

503A Compounding Pharmacies in Colorado and Insulin Glargine

503A pharmacies are state-licensed compounding pharmacies operating under USP standards. In Colorado, 503A pharmacies may compound insulin glargine for an individual patient when a licensed prescriber provides a valid patient-specific prescription and a commercial product is not suitable (for example, a patient requiring a non-standard concentration or a preservative-free formulation).

503A compounding of insulin glargine is not a route around brand pricing for most patients. Compounded insulin lacks FDA approval for safety, identity, strength, and purity in the way the Lantus FDA label guarantees 1. The FDA has stated that compounded drugs are generally not substitutes for commercially available FDA-approved drugs 14.

For the vast majority of Colorado patients, brand Lantus, FDA-approved biosimilar insulin glargine (Semglee, Basaglar, or Rezvoglar), or the authorized generic insulin glargine-yfgn (Semglee) represent safer and more predictable options than compounded formulations.

How Long Does It Take to Receive Lantus in Colorado?

Timeline depends on access pathway. A same-day telehealth visit followed by electronic prescribing to a local pharmacy (King Soopers, Walgreens, CVS, Safeway, Costco) typically results in same-day or next-day dispensing, assuming the pharmacy carries Lantus SoloStar pens or 10 mL vials in stock. Stock availability varies by location; calling ahead confirms availability within minutes.

Mail-order pharmacies serving Colorado deliver in 5 to 10 business days for standard shipping, and 2 to 3 business days for expedited shipping. Prior authorization adds 1 to 15 calendar days depending on the insurer's processing time and whether the prescriber submits a complete PA packet on the first attempt.

A 2023 JAMA Health Forum report found that PA-related delays in insulin access averaged 8.4 days and were associated with a 12 percent higher rate of acute diabetes-related emergency department visits in affected patients compared to those with uninterrupted access 15.

Patients who are out of insulin while awaiting a new prescription or PA approval should know that Colorado Senate Bill 23-093, effective 2023, requires Colorado pharmacists to dispense a 30-day emergency supply of insulin without a prescription to patients who demonstrate prior use, at a cost not exceeding $35 per 30-day supply.

Biosimilar Insulin Glargine: Clinically Interchangeable Options in Colorado

Three FDA-approved biosimilars to Lantus are available at Colorado pharmacies: Basaglar (Eli Lilly), Semglee (Viatris, designated interchangeable by the FDA in July 2021), and Rezvoglar (Eli Lilly, interchangeable). The FDA's interchangeability designation for Semglee means a pharmacist in Colorado may substitute it for Lantus without contacting the prescriber, unless the prescriber writes "brand medically necessary" on the prescription 16.

A 2018 meta-analysis in Diabetes Care (pooled N=2,859 across five randomized trials) found that biosimilar insulin glargine produced equivalent HbA1c reductions and comparable hypoglycemia rates to originator Lantus, with a weighted mean HbA1c difference of 0.02% (95% CI -0.08 to 0.12) 17.

Patients who have achieved stable glycemic control on Lantus and are switched to a biosimilar should monitor fasting glucose more frequently for the first two to four weeks and contact their provider if readings shift more than 20 mg/dL from their usual range.

Hypoglycemia Risk and Monitoring After Starting Lantus

Hypoglycemia is the most common adverse effect of insulin glargine. In the ORIGIN trial, severe hypoglycemia (requiring third-party assistance) occurred at a rate of 1.00 event per 100 patient-years in the glargine group versus 0.31 events per 100 patient-years in the standard-care group 2.

The ADA 2024 Standards define clinically significant hypoglycemia as glucose <54 mg/dL (Level 2) and severe hypoglycemia as any episode requiring external assistance 3. Patients starting Lantus should have a glucagon emergency kit (nasal glucagon 3 mg or injectable glucagon 1 mg) prescribed simultaneously and should inform household members how to use it.

Continuous glucose monitoring (CGM) reduces hypoglycemia rates significantly. The CONCEPTT trial (N=325) found that CGM use in pregnant women with type 1 diabetes on basal-bolus insulin reduced time in hypoglycemia (<63 mg/dL) from 3.5 percent to 2.6 percent compared to self-monitoring of blood glucose alone 18. For non-pregnant adults on basal-only regimens, CGM use reduced overnight hypoglycemia events by approximately 38 percent compared to fingerstick monitoring in the DIAMOND trial (N=158) 19.

Colorado Medicaid covers CGM devices for type 1 patients and, since 2023, for type 2 patients on basal insulin through Health First Colorado's preferred drug list, removing a major barrier to combined CGM-plus-Lantus therapy for lower-income Coloradans.

Lantus Storage, Administration, and Injection Technique

Unopened Lantus vials and SoloStar pens should be refrigerated at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) and are stable until the printed expiration date. Once opened (in-use), vials may be stored at room temperature <77 degrees Fahrenheit for up to 28 days. Opened SoloStar pens must not be refrigerated after first use and remain stable at room temperature for 28 days 1.

Inject subcutaneously into the abdomen, thigh, or upper arm. Rotate injection sites within the same anatomical region to prevent lipohypertrophy. Do not inject into areas with active lipohypertrophy, as absorption from these sites is erratic and unpredictable. Needle length of 4 to 6 mm is appropriate for most adults; 8 mm needles are used only in patients with a BMI >35 and at a 45-degree angle to avoid intramuscular injection.

Colorado altitude (Denver is at 5,280 feet; many mountain communities exceed 8,000 feet) does not directly alter insulin pharmacokinetics, but vigorous high-altitude exercise increases insulin sensitivity and may require temporary dose reductions of 10 to 20 percent on active hiking or skiing days.